Definium Therapeutics
DFTX
157 hedge funds and large institutions have $282M invested in Definium Therapeutics in 2024 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 51 increasing their positions, 29 reducing their positions, and 21 closing their positions.
79% more call options, than puts
Call options by funds: $4.76M | Put options by funds: $2.67M
76% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 29
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
4% more funds holding
Funds holding: 151 → 157 (+6)
3.03% more ownership
Funds ownership: 57.79% → 60.82% (+3%)
6% less capital invested
Capital invested by funds: $299M → $282M (-$17.7M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
+$14M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$9.43M |
| 3 |
TLP
Tri Locum Partners
New York
|
+$8.91M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$6.69M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
+$6.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$7.27M |
| 2 |
Two Sigma Investments
New York
|
-$2.81M |
| 3 |
ABG
Ally Bridge Group
New York
|
-$1.23M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$696K |
| 5 |
AGM
Alpine Global Management
New York
|
-$492K |
DFTX Hedge Fund Activity: Q3 2024 in Review
157 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q3 2024, worth a combined $282M — down 5.9% from $299M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new DFTX positions and 21 closed out — a net gain of 8 holders — while 51 added to existing stakes and 29 trimmed.
The largest buyer was Blackstone Inc, adding an estimated $14M. The largest seller was Artal Group, exiting entirely with an estimated $7.27M sold.
- 157 institutional investors held Definium Therapeutics (DFTX) as of Q3 2024, up from 151 in Q2 2024.
- Funds reported $282M of Definium Therapeutics stock for Q3 2024, down 5.9% quarter-over-quarter.
- 29 funds opened new Definium Therapeutics positions in Q3 2024 and 21 closed out, a net change of +8 holders.
- The largest Definium Therapeutics buyer in Q3 2024 was Blackstone Inc, an estimated $14M added.
- The largest Definium Therapeutics seller in Q3 2024 was Artal Group, an estimated $7.27M sold.
Based on aggregated 13F filings for Q3 2024.